ADCT-241: PSMA-Targeted Antibody–Drug Conjugate Shows Bystander Activity in Prostate Cancer Models

/in , /by

A new preclinical study published in Molecular Cancer Therapeutics reports encouraging results for ADCT-241, an experimental antibody–drug conjugate (ADC) designed to target prostate-specific membrane antigen (PSMA) in prostate cancer. ADCT-241 combines a PSMA-targeting antibody with a cytotoxic payload derived from exatecan, a topoisomerase I inhibitor. Unlike PSMA-targeted radioligand therapies, which deliver radiation to tumour cells, […]

Read more

A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response

/in , /by

A newly published study has introduced an interesting variation on antibody-drug conjugates (ADCs) for advanced prostate cancer: instead of simply delivering a toxic payload to cancer cells, the treatment is designed to help the immune system recognise what remains. The experimental ADC targets STEAP1, a cell-surface protein highly expressed in prostate cancer and already being […]

Read more

Blocking BCL-XL Increases ADC Effectiveness

/in , /by

UCLA researchers have reported a promising way to improve antibody-drug conjugates, or ADCs, in metastatic castration-resistant prostate cancer, a disease that remains difficult to control once it stops responding to hormone therapy. Their work suggests that pairing ADCs with a drug that blocks BCL-XL can make prostate cancer cells more vulnerable, leading to greater cell […]

Read more

A New Immune‑Engaging ADC Platform: STEAP1‑Targeted Vandortuzumab–Exatecan

/in , , /by

Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]

Read more

MMAE-Based LIV1 ADC Achieves Sustained Tumor Control in Prostate Cancer Models

/in , /by

LIV1, a zinc transporter protein, sits on the surface of 72% of prostate tumors with minimal expression in healthy tissues. This makes it an ideal target for antibody-drug conjugates, a therapeutic class combining antibody specificity with potent cytotoxic payloads. Researchers developed 48D6, a humanized anti-LIV1 monoclonal antibody with substantially improved pharmacokinetics compared to previous versions. […]

Read more

MUC1‑C Targeting with XYA02‑8‑ADC, for Castration‑Resistant and Neuroendocrine Prostate Cancer

/in , /by

In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in […]

Read more

NEOK001: A New Bispecific Antibody–Drug Conjugate for Advanced Prostate Cancer

/in , /by

A promising new experimental drug called NEOK001 (also known as ABL206) is emerging as a potential therapy for advanced cancers that express two specific proteins on their surface: B7‑H3 and ROR1. Among these cancers, prostate cancer is one of the tumor types where early data already show signs of activity, making NEOK001 a candidate of […]

Read more

SHR-A1921: A Next-Generation TROP2-Targeted Antibody-Drug Conjugate Shows Promise in Prostate Cancer

/in , /by

SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]

Read more

Smart Antibody Medicines: How the ALCO5 Platform Could Upgrade Targeted Cancer Therapy

/in , , /by

ALCO5 is a new way of building “smart” cancer drugs that combine an antibody with a powerful medicine in a single, targeted package. The aim is to hit cancer cells much harder while sparing as much healthy tissue as possible, and to do this with drug types that previously could not be used in these […]

Read more